The collection of data which will help define the natural history of the recurrence of hepatitis C (HCV) in patients of liver transplant. Approximately 4000 patients undergo liver transplantation each year in the United States. Cirrhosis (scarring) caused by hepatitis C accounts for approximately 33% of these patients and is the single most common cause of liver transplantation in the U.S. and in other countries. Disease recurrence is prominent and has been observed in 90-95% of patients following transplantation. Fortunately, recurrent HCV is not a rapidly progressing process. The primary goal of this planning grant is to demonstrate if this multi-centered group can gather preliminary data, organize core laboratory facilities, and develop a manual of operations which will be necessary to conduct a definitive multi-centered clinical trial designed to prevent recurrent HCV following liver transplant. The subjects in this study will either require a liver transplant or will have already undergone a transplant. During the patient evaluation for this procedure, patients will undergo a series of tests to help define their operative and post operative risks for survival, to more accurately define the severity of the disease, and the urgency for transplantation. After the surgery, the transplant team will follow the patients on a regular basis. Doses of immunesuppressant medication will be adjusted. Evidence of rejection and recurrence of HCV will be monitored. This study will analyze data on all patients who underwent transplants at the Medical College of Virginia. This will include data regarding the cause of cirrhosis, the severity of cirrhosis, and specific data regarding chronic HCV infection prior to undergoing transplantation. Following transplant, all laboratory data and liver biopsy specimens will be collected. This data will be used to determine if and how chronic HCV contributes to disfunction. All patients who do not have chronic HCV will be used as a control group.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000065-38
Application #
6419290
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1977-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
38
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93
Jones, Robert; Vuky, Jacqueline; Elliott, Tony et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs 31:1001-7
Al Hawaj, M A; Martin, E J; Venitz, J et al. (2013) Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia 19:409-14
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8

Showing the most recent 10 out of 367 publications